The neurologist’s dilemma: A comprehensive clinical review of Bell’s palsy, with emphasis on current management trends

Anthony Zandian
Stephen Osiro
Ryan Hudson
Irfan M. Ali
Petru Matusz
Shane R. Tubbs
Marios Loukas

Background:
Recent advances in Bell’s palsy (BP) were reviewed to assess the current trends in its management and prognosis.

Material/Methods:
We retrieved the literature on BP using the Cochrane Database of Systematic Reviews, PubMed, and Google Scholar. Key words and phrases used during the search included ‘Bell’s palsy’, ‘Bell’s phenomenon’, ‘facial palsy’, and ‘idiopathic facial paralysis’. Emphasis was placed on articles and randomized controlled trials (RCTs) published within the last 5 years.

Results:
BP is currently considered the leading disorder affecting the facial nerve. The literature is replete with theories of its etiology, but the reactivation of herpes simplex virus isoform 1 (HSV-1) and/or herpes zoster virus (HZV) from the geniculate ganglia is now the most strongly suspected cause. Despite the advancements in neuroimaging techniques, the diagnosis of BP remains one of exclusion. In addition, most patients with BP recover spontaneously within 3 weeks.

Conclusions:
Corticosteroids are currently the drug of choice when medical therapy is needed. Antivirals, in contrast, are not superior to placebo according to most reliable studies. At the time of publication, there is no consensus as to the benefit of acupuncture or surgical decompression of the facial nerve. Long-term therapeutic agents and adjuvant medications for BP are necessary due to recurrence and intractable cases. In the future, large RCTs will be required to determine whether BP is associated with an increased risk of stroke.

MeSH Keywords:
Bell Palsy • Herpes Simplex Virus Protein Vmw65 • Hydrocortisone
Background

Bell's palsy is an acute, ipsilateral, facial nerve (CN VII) paralysis of unknown etiology that results in weakness of the platysma and muscles of facial expression [1]. Nicolaus Friedrich, an 18th century professor of medicine at Wurzburg, may have been the first to publish a case report of a facial nerve paralysis of unknown origin [2]. He gave an account of 3 middle-aged adults who had a similar onset of acute or subacute unilateral facial paralysis, which gradually improved over a period of weeks to months [2]. His clinical findings, De paralysis Musculorum Faciei Rheumatica, were first published in 1798 in the German medical literature.

Two years later, this paper was reviewed in English and published in the Annals of Medicine in Edinburgh. Around that time, a young Charles Bell (Figure 1) was studying medicine at the institution, and may have read Friedrich’s paper [3]. Bell later studied the function of the facial nerve in animals [2]. While practicing surgery in London, he encountered many cases of unilateral facial nerve paralysis and published his first report in 1821 [4]. Interestingly, his most famous and widely quoted account of facial paralysis was published in 1828, in which he told the story of a man who had been tossed by a bull. The ensuing puncture wound led to a lasting paralysis of his facial nerve [2].

Although Bell’s initial publication on facial paralysis came after Friedreich’s account by 23 years, Grzybowski argues that Bell deserves the credit for differentiating peripheral from central facial nerve paralysis [4]. Today, the term Bell’s palsy is synonymous with idiopathic peripheral facial paralysis.

Recent advances in neuroimaging techniques such as MRI have equipped modern physicians with a considerable advantage over their predecessors in respect to visualizing the facial nerve. However, to our knowledge, there is no consensus on the etiological explanation or the preferred long-term treatment option for Bell’s palsy. In this review, we aim to provide the most comprehensive understanding of Bell’s palsy to date, with emphasis on clinical implications and the preferred management strategies based on reports from the recent literature.

Epidemiology

Bell’s palsy (Figure 2) is the most common disorder affecting the facial nerve [5] and is responsible for about 80% of all facial mononeuropathies [6]. Ramsey Hunt syndrome, which is a complication of the varicella-zoster virus infection, is the second leading cause of hemifacial paralysis [7]. Epidemiological studies report that Bell’s palsy affects 11–40 persons per 100,000 each year, with peak incidence usually between the ages of 15 and 50 years [8–10]. In the United States alone, more than 60,000 cases are diagnosed annually [11], with similar incidence rates reported among males and females [12]. Pregnant women, often during the third trimester and early postpartum periods, have also been shown to have higher incidence and risk of Bell’s palsy – up to 3 times greater compared to the general population [5,13]. Other susceptible groups include diabetics [1,14–16], the elderly [17–19], and patients with hypothyroidism [6].
Anatomy

Knowledge of the course and function of the facial nerve (CN VII) is crucial to understanding the pathophysiology of Bell’s palsy. The nerve provides efferent motor innervation to the muscles of the face, the stapedius, and posterior belly of the digastric muscles (Figure 3A) [7]. In addition, sensory and parasympathetic fibers travel with the facial nerve. These parasympathetic fibers supply the lacrimal gland via the greater superficial petrosal nerve, and the submandibular glands via chorda tympani (Figure 3B). It is therefore not surprising that all of these fibers are susceptible to paralysis if the facial nerve is affected.

CN VII enters the temporal bone at the internal acoustic meatus, continues via the fallopian canal, and exits through the stylomastoid foramen. The narrowest portion of the fallopian canal is at the lateral end of the internal auditory canal [7]. The most probable mechanism of Bell’s palsy is an inflammatory process of the facial nerve leading to its compression along this narrow segment of the fallopian canal [20,21]. This inflammation initially causes a temporary loss of sensory or motor function, but can lead to permanent nerve degeneration later [20].

Mechanism and Etiology

The mechanism of Bell’s palsy has been the subject of fierce debate for decades, with the underlying cause of neuropathy remaining elusive despite several proposed theories. One theory describes BP as an acute demyelinating disease, which may have a similar pathogenic mechanism as Guillain-Barré syndrome [22,23]. It has been suggested that they both represent an inflammatory demyelinating neuritis in which BP can be considered a mononeuritic variant of Guillain-Barré [23,24].

Based on recent reports, the suspected etiology could be due to the reactivation of latent herpes viral infections in the geniculate ganglia, and their subsequent migration to the facial nerve [9,25]. Herpes simplex virus 1 (HSV-1) and herpes zoster virus (HZV) may be the causative agents, with HZV believed to be the more aggressive virus since it spreads across the nerve by means of satellite cells [9]. These reports are in agreement with the earlier findings of Murakami et al., who successfully isolated HSV-1 DNA from the endoneural fluid of the facial nerve by polymerase chain reaction (PCR) during the acute phase of Bell’s palsy [26]. As previously mentioned, the literature supports the idea of herpes simplex virus-mediated inflammation leading to nerve compression and clinical features such as facial paralysis [25,27,28].

Recently, the inactivated intranasal influenza (flu) vaccine has also been linked with Bell’s palsy [29]. Mutsch et al. performed a matched case-control study with case-series analysis, during which they looked at whether the 773 Bell’s palsy patients had also received the flu vaccine [29]. After adjusting for other variables, they reported that a strong temporal and specific association did exist; the risk of developing Bell’s palsy in patients who received the vaccine was nearly 19 times that of control groups without flu vaccine. Mutsch’s study found peak incidence of Bell’s palsy at 31 to 60 days after vaccination. From that data, it has been suggested that the activation of Bell’s palsy is not due to a direct toxic effect from the vaccine, but rather an autoimmune disorder or reactivation of HSV [30]. It is worth noting that the vaccine is no longer in clinical use. There was also no association of the palsy with parenteral flu vaccines.

Other known documented infectious causes of Bell’s palsy include: adenovirus, Coxsackie virus, cytomegalovirus,
Epstein-Barr virus, influenza, mumps, and rubella [31]. Rickettsia is a rare infectious cause [32]. Suggested non-infectious causes of Bell's palsy include autoimmune processes such as Hashimoto's encephalopathy [33,34], ischemia from atherosclerosis leading to facial nerve edema [6,18,19], and familial origin, with about 4% to 8% of Bell's palsy patients reported to have an associated family history [5].

**Clinical Presentation**

Bell's palsy typically presents with a sudden and rapid onset of unilateral facial weakness, often within a few hours [7]. In fact, the symptoms can be so startling that most of the affected individuals either think they have had a stroke or a serious brain lesion [9]. It is important to note that up to 60% of these patients report a preceding viral illness [35].

Initially, partial palsy is reported by most patients, with maximum facial weakness often seen within 2 days [7,9]. Patients may also complain of ipsilateral earache as well as numbness of the face, tongue, and ear [25]. Moreover, cases of hyperacusis (possibly from stapedial muscle dysfunction), tinnitus, taste disturbances (most likely from injury to nervus intermedius proximal to geniculate ganglion), and decreased lacrimation have also been reported [5,6,9].

The motor deficit is almost always unilateral in Bell's palsy [6], with both the upper and lower parts of the face affected. This helps to distinguish the disorder from a central supranuclear lesion, in which paresis occurs only in the lower facial muscles [6]. An often overlooked psychological component may also exist in patients presenting with acute Bell's palsy, in which the acute onset of the condition can drastically affect social activity [36].

**Diagnosis and Investigations**

Because Bell's palsy involves the peripheral facial nerve, there is often impaired ipsilateral movement of the affected side of the face, drooping of the eyebrow and corner of the mouth, as well as the loss of the ipsilateral nasolabial fold (Figure 2). Bell's phenomenon – the upward movement of the eye on attempted closure of the lid due to weakness of the orbicularis oculi – is a pathognomonic sign [6,37].

Apart from diffuse facial nerve paralysis, Bell's palsy is typically characterized by an acute onset, with symptoms presenting within several days and eventual resolution by 4 months. A progressive and prolonged course with frequent relapses and no recovery suggests neoplastic process [38].

Bell's palsy must be differentiated from other facial paralyses, as there is a 13–20% rate of misdiagnosis [7]. Conditions that may mimic Bell's palsy include CNS neoplasms, stroke, HIV infection, multiple sclerosis, Guillain-Barré syndrome, Ramsay-Hunt syndrome, Melkersson-Rosenthal syndrome, Lyme disease, otitis media, cholesteatoma, sarcoidosis, trauma to the facial nerve, autoimmune diseases such as Sjogren's syndrome, and metabolic disorders such as diabetes mellitus [5,7,20,39]. Bell's palsy is typically diagnosed by exclusion, and a thorough history and physical exam is needed to rule out other treatable or intracranial lesions [5]. Ear function should routinely be tested using tuning forks and standard pneumatic otoscopes. Clinical evidence of herpes zoster infection may help aid in the diagnosis of Bell's palsy. However, vesicular lesions may be absent in the presence of pre-herpetic neuralgia in a clinical condition termed Zoster sin herpete [9].

The modified House-Brackmann scale (1985) is a clinical tool used to document the degree of facial paralysis and to predict probability of recovery. It assesses gross facial features and symmetry, both at rest and during motion. The grading is from 1 to 6, with the latter being total paralysis [7,40]. Patients who present with some observable facial movement and incomplete paralysis are expected to have uniformly good recovery. Patients with a House-Brackmann score of 6 may have prolonged or incomplete recovery [41]. The Sunnybrook facial grading system, Yanagihara grading system, and Sydney grading system represent regional alternatives to the House-Brackmann scale and have similar reliability, although reported ease of use varies [42–46]. The House-Brackmann scale is currently the most widely used and accepted.

Laboratory and imaging studies are not routinely needed in the diagnosis of Bell's palsy and are only recommended in patients with recurrence, or if there has been no improvement after more than 3 weeks of therapy [47].

It is still recommended that patients with Bell's palsy be referred to a neurologist or otolaryngologist as soon as possible to rule out more serious neurological conditions [35]. Serological tests to rule out Lyme disease are essential in endemic areas [5]. It is important to note that while Bell's palsy is rare in children younger than 10 years old, as many as 50% of the reported cases of facial palsy in this group are due to Lyme disease [5].

Electromyography (EMG) and motor nerve conduction studies of the facial nerve can yield useful information on the viability of the affected nerve, thus aiding in the decision making process regarding treatment and/or surgical management of disease [48]. These electrodiagnostic studies yield information on the amount of evoked action potentials in affected muscles. Using this data, clinicians can estimate the amount of axonal...
loss. Patients exhibiting greater than 90% axonal degeneration should be considered for surgical decompression, while axonal degeneration of less than 90% has a favorable prognosis [49]. These studies are clinically useful within 2 weeks of complete facial paralysis [1]. After 3 months of onset of symptoms, needle electromyography may be employed to confirm any subclinical signs of re-innervation, thus acting as a prognostic indicator for the possibility of recovery [48].

Up to 5% of all lower motor neuron facial paralysis may be due to benign and malignant neoplasms [50]. Furthermore, a recent longitudinal study in Taiwan found a statistically significant increased risk of cancer in BP patients at 5-year follow-up [51]. If there is clinical suspicion, imaging studies such as CT with contrast or gadolinium-enhanced MRI are useful in ruling out neoplasms [5]. It is suggested that any case of BP without resolution within 4 months or first presenting 4 months after symptom onset undergo contrast-enhanced imaging of the parotid gland, temporal bone, and brain. Repeat imaging is indicated if symptoms persist at 7 months without a readily identifiable cause. Biopsy of affected tissue adjacent to the facial nerve may then be considered if imaging is negative at 7 months [52].

Management of Bell's Palsy

Because the exact cause is still unknown, Bell's palsy has no prevention or cure [39]. Thus, attempts at management over the years have been geared toward reducing inflammation to the facial nerve and/or preventing corneal complications stemming from paresis of the facial muscles [7].

Protecting the cornea from excessive dryness and abrasions should be addressed by the clinician through proper patient education. The cornea of patients with BP is especially at risk of drying because of improper lid closure and decreased tear production. Prescription of hourly lubricating eye drops and eye ointment during sleep are recommended [9]. In addition, the clinician should be prepared to provide psychological support in the early stages of management [9].

Both the preferred and optimum medical therapies for Bell's therapy are still deliberated, with several randomized controlled trials (RCTs) showing mixed results [25,35]. The past 2 decades have consequently seen an increased number of trials, not only with anti-herpetic medications and corticosteroids, but also alternative techniques such as acupuncture and physical therapy. The quest for these alternative therapies probably stemmed from early data that failed to show any significant effect of drugs in treating Bell's palsy. A Cochrane review of 4 RCTs conducted in 2004, for instance, showed that corticosteroids were no better than placebo [53], and another review of 3 trials in the same year also concluded that antivirals had no effect in the resolution of Bell's palsy [54].

Recently, however, evidence has been mounting in support of corticosteroid as the treatment of choice [55–63]. Two RCTs by Sullivan et al. on 496 patients, and 1 on 839 patients by Engstrom et al., showed that early treatment with prednisone significantly improved the recovery of facial nerve function at 3- and 9-month intervals [58,62]. These studies also confirmed that the use of antivirals was inconsequential, whether given alone or with prednisone. Moreover, they noted that measuring each patient's baseline severity of the palsy could provide information on which patients are more likely to benefit from corticosteroid treatment.

A meta-analysis by de Almeida et al. on 10 trials, assessing the efficacy of prednisolone versus placebo in the management of Bell's palsy, also reported an overall significant benefit to treatment using prednisolone, with the number needed to treat (NNT) at 11 [57]. These findings were corroborated by a recent Cochrane review of 8 RCTs with over 1500 patients (2010), which validated the benefit of treating Bell's palsy patients with corticosteroids. Of the 754 patients who were treated with corticosteroids, the authors noted that only 23% had incomplete recovery of facial motor function at 6 months, compared to 33% of patients who were given the placebo. In addition, they noted that the patients who had received corticosteroids had a significant reduction in motor synkinesis during follow-up compared to their counterparts [64].

Antiviral agents against HSV have also been extensively used to treat Bell's palsy, and their effectiveness has been increasingly disputed based on recent studies. A 2009 Cochrane systematic review of 7 high-quality trials with 1987 participants concluded that anti-herpetic antivirals provide no significant benefit compared with placebo in generating complete recovery from Bell's palsy [65]. Although antivirals alone do not provide a clear benefit, the efficacy of corticosteroids plus antivirals is less clear. Several studies have found no significant benefit from using combined antiviral and glucocorticoid treatment [66]. Recently, a network meta-analysis of 6 studies with a total of 1805 patients from 1996 to 2008 showed that a combination of corticosteroids with antivirals had a marginal benefit over corticosteroids alone [61]. However, since the findings did not reach statistical significance, the authors concluded that prednisone remains the single best evidence-based treatment for Bell's palsy [61]. A 2013 study in Korea found a statistically significant improvement in patients with severe facial palsy when given famciclovir plus steroids within 1 week of presentation vs. steroids alone [67]. These results are promising, but it is unlikely that additional studies will significantly change current clinical practice due to the modest benefit of adding antivirals [68]. It has been proposed that research efforts should
instead focus on the dosage and timing of steroid treatment, and treatment outcomes in specified age groups [68].

The literature shows no consensus for the benefit of, or indication for, surgery in the treatment of Bell’s palsy [46,69,70–73]. Risks associated with surgical decompression include seizures, unilateral hearing loss, CSF leak, and facial nerve injury [9,71,73]. Surgical decompression of the facial nerve therefore remains highly controversial and should only be considered in refractory cases, given the low-quality and inconclusive nature of the reports on its use. The proposed algorithm for managing severe Bell’s palsy is shown in Figure 4.

Despite the advocacy of its use by some authors, acupuncture has not been proven to have any effect on either the recovery process or long-term morbidity from Bell’s palsy [74]. A recent 2013 RCT by Xu, however, does show promise in the utilization of acupuncture alongside glucocorticoid treatment. Patients undergoing intense acupuncture stimulation and glucocorticoid treatment had better 6 month outcomes according to the House-Brackmann scale vs. patients receiving standard acupuncture plus glucocorticoids [75]; the findings are promising, but additional high quality trials will be required before its efficacy can be validated.

Electrical nerve stimulation is a proposed method of accelerating recovery in BP patients through invoked muscle stimulation. Further studies will be required to assess clinical applicability [76–79].

**Figure 4.** Proposed algorithm for the management of severe Bell’s palsy. FP, facial palsy; EMG, electromyography; D15, fifteen days after onset of palsy (Redrawn and modified with permission from Bodenez et al., 2010).

**Prognosis**

Most patients with Bell’s palsy regain normal function with or without medical therapy, often within 3 weeks [6,80]. In some cases, full recovery takes up to 9 months [5], but up to 30% are left with potentially disfiguring facial weakness, involuntary movements, and/or persistent lacrimation, requiring further interventions [25,39,71]. A delay in the diagnosis and administration of medications could play a role in residual weakness of the face and mouth, but other factors such as severity of the inflammation and compression of the facial nerve are equally significant. Age and the degree of facial paralysis are other reported prognostic factors, with younger patients and those with partial facial palsy gaining almost full restoration [5]. Patients who exhibit signs of recovery within 21 days of symptom onset have a favorable prognosis [81].

Electrodiagnostic testing is helpful in identifying severe cases of Bell’s palsy [6]; however, it must be done in a timely manner because decompression of the facial nerve later than 14 days after onset of symptoms does not alter the prognosis of Bell’s palsy [82]. It must also be remembered that almost all patients with Bell's palsy do regain some function within 3 months of onset; hence, all affected individuals should be re-evaluated at that time to rule out tumor as the cause of the facial paresis.

The recurrence rate of Bell’s palsy is about 12% of cases, with 36% re-experiencing paralysis on the same side [5,39]. Multiple recurrences are relatively rare, occurring in about 3% of cases. BP recurrence does not seem to be correlated with prognosis [83].

**Complications of Bell’s Palsy**

Long-term complications can develop from Bell’s palsy. For instance, when nerve fibers have been damaged, they may aberrantly regenerate by connecting with the lacrimal ducts instead of the salivary glands. This can lead to lacrimation while eating, or “crocodile tears” [6]. Similarly, regenerating motor neurons can innervate inappropriate muscles, which leads to abnormal movements or facial synkinesis [6]. Botulinum toxin injection and facial reanimation through cosmetic surgery are among the proposed methods of treating such long-term sequelae [9,84–86]. Long-term patient satisfaction and quality of life may be monitored using the Facial Clinimetric Evaluation Scale (FaCE) in conjunction to the House-Brackmann scale in these instances [87].

Most recently, Chiu et al. reported that Bell’s palsy can increase the risk of non-hemorrhagic stroke [88]. In a population-based cohort study of 7506 Bell’s palsy patients and 22 158 non-BP...
patients followed for 2 years, they found that Bell’s palsy pa-
tients were at an increased risk (4%) of stroke compared to
the general population (1.6%) after adjusting for co-morbid-
ties [88]. Their finding can partly be explained by the fact that
previous studies have shown an increased risk of stroke in pa-
tients with HSV-1 and HZV [89]. These pathogens have been
suggested to cause inflammation as well as atherosclerosis and
vasculopathy in the cerebral vasculature [90,91].

Conclusions

Based on our review, the cause of Bell’s palsy remains elu-
sive, but herpetic reactivation is now the most strongly sus-
pected cause. Its clinical presentation is well-documented in
the literature. However, the diagnosis is still one of exclusion.
While prior systematic reviews showed no difference between
medical therapy and placebo in treating Bell’s palsy, results of
recent RCTs strongly recommend corticosteroids as the treat-
ment of choice. Antiviral therapy is of no significant help ac-
cording to most reliable studies. Surgical treatment of Bell’s
palsy is still controversial, and should only be used for refrac-
tory cases.

Acknowledgements

The authors wish to thank Jessica Holland, MS, Medical
Illustrator in the Department of Anatomical Sciences, St Georges
University, Grenada, West Indies, for the creation of her illus-
trations used in this publication.

References:

1. Gilden DH: Clinical practice. Bell’s Palsy. N Engl J Med, 2004; 351(13):
2. Bird TD, Nicolaus A: Friedrich’s description of peripheral facial nerve pa-
ralysis in 1778. J Neurol Neurosurg Psychiatry, 1979; 42(1): 56–58
3. Zimmerman LM: The Founders of Neurology. Springfield (IL): Charles C.
6. Goroll AH, Mulley AG: Primary care medicine: office evaluation and man-
agement of the adult patient, 6th ed. Philadelphia (PA): Lippincott Williams &
9. Holland NJ, Weiner GM: Recent developments in Bell’s palsy. [Review]. BMJ,
12. Bosco D, Plastino M, Bosco F et al: Bell’s palsy: a manifestation of predia-
abetes? Acta Neurol Scand, 2011; 123(1): 68–72
16. Riga M, Kefalidis G, Danielides V: The role of diabetes mellitus in the clin-
cal presentation and prognosis of bell palsy. JABFM, 2012; 25(6): 819–26
19. Raff MC, Asbury AK: Ischemic mononeuropathy and mononeuropathy mul-
tiplex in diabetes mellitus. N Engl J Med, 1968; 279: 17–22
21. Liu J, Li Y, Yuan X, Lin Z: Bell’s palsy may have relations to bacterial infec-
tion. Med Hypotheses, 2009; 72(2): 169–70
22. Aviel A, Ostfeld E, Burstein R et al: Peripheral blood T and B lymphocyte
subpopulations in Bell’s palsy. Ann Otol Rhinol Laryngol, 1983; 92: 187–91
23. Greco A, Gallo A, Fusconi M et al: Bell’s palsy and autoimmune. Autoimmun
Rev, 2012; 12: 323–28
24. Chaco J: Subclinical peripheral nerve involvement in unilateral Bell’s pal-
sy. Am J Phys Med, 1973; 52: 195–97
25. Schirm J, Mulken PS: Bell’s palsy and herpes simplex virus. APMIS, 1997;
105: 815–23
26. Murakami S, Mizobuchi M, Nakashiro Y et al: Bell’s palsy and herpes sim-
plex virus: identification of viral DNA in endoneurial fluid and muscle. Ann
Intern Med, 1996; 124(1): 27–33
27. Baringer JR: Herpes simplex virus and Bell palsy. Ann Intern Med, 1996;
124(1 Pt 1): 63
28. Peitersen E: Bell’s palsy: The spontaneous course of 2,500 peripheral facial
nerve palsies of different etiologies. Acta Otolaryngol Suppl, 2002; [S49]:
4–30
29. Mutsch M, Zhou W, Rhodes P et al: Use of the inactivated intranasal influ-
enza vaccine and the risk of Bell’s palsy in Switzerland. N Engl J Med, 2004;
350(9): 896–903
30. Couch RB: Nasal vaccination, Escherichia coli enterotoxin, and Bell’s palsy.
N Engl J Med, 2004; 350(9): 860–61
31. Morgan M, Nathwani D: Facial palsy and infection: the unfolding story. Clin
Infect Dis, 1992; 14(1): 263
32. Bitsori M, Galanakis E, Papadakis CE, Sbyrakis S: Facial nerve palsy associ-
ated with Rickettsia conorii infection. Arch Dis Child, 2001; 85(1): 54
33. Schaitkin BM, May M, Podvines M et al: Idiopathic (Bell’s) palsy, herpes
zoster cephalicus, and other facial nerve disorders of viral origin. In: May M,
Schaitkin BM (eds.), The facial nerve: May’s 2

Indexed in: [Current Contents/Clinical Medicine] [SciVerse ScienceDirect] [ISI Alerting System] [ISI Journals Master List] [ISI Expanded] [ISI Web of Science] [CMEDLINE] [CAB Abstracts] [Chemical Abstracts/CAS] [EMBASE/Excerpta Medica] [Index Copernicus]
42. Berg T, Jonsson L, Engstrom M: Agreement between the Sunnybrook, House-Brackmann, and Yanagihara facial nerve grading systems in Bell's palsy. Otol Neurotol, 2004; 25(6): 1020–26

43. Coulson SE, Croxson, Adams RD, O'Dwyer NJ: Reliability of the “Sydney,” “Sunnybrook,” and “House Brackmann” facial grading systems to assess voluntary movement and synkinesis after facial nerve paralysis. Otalaryngol Head Neck Surg, 2005; 132(4): 543–49

44. Marsk E, Bylund N, Jonsson L et al: Prediction of nonrecovery in Bell's palsy using Succinylcholine Drazing. Laryngoscope, 2012; 122(6): 901–90

45. Yanagihara N, Gyo K, Yumoto E, Tamaki M: Transmastoid decompression of the facial nerve in Bell's palsy. Arch Otalaryngol, 1979; 105(9): 530–34

46. Yanagihara N, Hato N, Murakami S, Honda N: Transmastoid decompression as a treatment of Bell palsy. Otol Head Neck Surg, 2001; 24(3): 282–86

47. Bodenez C, Bernat I, Willer JC et al: Facial nerve decompression for idiopathic Bell's palsy: report of 13 cases and literature review. J Laryngol Otol, 2010; 124(3): 272–78

48. Valls-Sole J: Electrodiognostic studies of the facial nerve in a peripheral facial palsy and femicfacial spasms. Muscle Nerve, 2007; 36(1): 14

49. Shularick NM, Mowey SE, Soken H, Hansen MR: Is electronueurography beneficial in the management of bell’s palsy? Laryngoscope, 2013; 123: 1066–67

50. Selesnick SH, Patwardhan A: Acute facial paralysis: evaluation and early management. Am J Otalaryngol, 1994; 15: 387–408

51. Sheu JI, Keller JI, Lin H: Increased risk of cancer after Bell's palsy: a 5-year follow up study. J Neurooncol, 2012; 110(2): 215–20

52. Quesnel AM, Lindsay RW, Hadlock TA: When the bells toll on Bell's palsy: finding occult malignancy in acute-onset facial paralysis. Am J Otalaryngol, 2010; 31(5): 339–42

53. Salinas RA, Alvarez G, Ferreira J: Corticosteroids for Bell's palsy (idiopathic facial paralysis). Cochrane Database System Rev, 2004; 3: CD001942

54. Allen D, Dunn L: Aciclovir or valaciclovir for Bell's palsy (idiopathic facial paralysis). Cochrane Database Syst Rev, 2004; 4: CD001869

55. Pitts DB, Adour KK, Hilsinger RL: Recurrent Bell's palsy: analysis of 140 patients. Laryngoscope, 1988; 98(5): 535

56. Douglas RS, Gaussa RE: A systematic comprehensive approach to management of irreversible facial paralysis. Facial Plast Surg, 2003; 19(1): 107

57. Ito H, Hato H, Nakano S, Kusaka H: Low-dose subcutaneous injection of botulinum toxin type A for facial synkinesis and hyperlacrimation. Acta Neurol Scand, 2007; 115(4): 271

58. Nava-Castaneda A, Toivilla-Canales JL, Boloussa V et al: Duration of botulimum toxin effect in the treatment of crocodile tears. Ophal Plast Reconstr Surg, 2006; 22(6): 453

59. Ng NH, Ngo RW: The use of the facial clinimetric evaluation scale as a patient based grading system in bell's palsy. Laryngoscope, 2008; 118: 635–43

60. Van Gijn J: Charles Bell (1774–1842). J Neurol, 2011; 258(6): 1189–90